CA2923614C - Phtalazinone derivatives and manufacturing process thereof - Google Patents
Phtalazinone derivatives and manufacturing process thereof Download PDFInfo
- Publication number
- CA2923614C CA2923614C CA2923614A CA2923614A CA2923614C CA 2923614 C CA2923614 C CA 2923614C CA 2923614 A CA2923614 A CA 2923614A CA 2923614 A CA2923614 A CA 2923614A CA 2923614 C CA2923614 C CA 2923614C
- Authority
- CA
- Canada
- Prior art keywords
- carbonyl
- phthalazin
- fluoro
- azetidine
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130110170 | 2013-09-13 | ||
| KR10-2013-0110170 | 2013-09-13 | ||
| KR10-2014-0120152 | 2014-09-11 | ||
| KR1020140120152A KR101670126B1 (ko) | 2013-09-13 | 2014-09-11 | 신규 프탈라지논 유도체 및 그 제조방법 |
| PCT/KR2014/008523 WO2015037939A1 (en) | 2013-09-13 | 2014-09-12 | A novel phtalazinone derivatives and manufacturing process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2923614A1 CA2923614A1 (en) | 2015-03-19 |
| CA2923614C true CA2923614C (en) | 2017-06-27 |
Family
ID=53024930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2923614A Active CA2923614C (en) | 2013-09-13 | 2014-09-12 | Phtalazinone derivatives and manufacturing process thereof |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | USRE49338E1 (enExample) |
| EP (1) | EP3030557B1 (enExample) |
| JP (1) | JP6180643B2 (enExample) |
| KR (1) | KR101670126B1 (enExample) |
| CN (1) | CN105793248B (enExample) |
| AU (1) | AU2014319132C1 (enExample) |
| BR (1) | BR112016004979B1 (enExample) |
| CA (1) | CA2923614C (enExample) |
| DK (1) | DK3030557T3 (enExample) |
| ES (1) | ES2953834T3 (enExample) |
| FI (1) | FI3030557T3 (enExample) |
| HR (1) | HRP20230998T1 (enExample) |
| HU (1) | HUE062770T2 (enExample) |
| IL (1) | IL244548B (enExample) |
| LT (1) | LT3030557T (enExample) |
| MX (1) | MX379467B (enExample) |
| MY (1) | MY195343A (enExample) |
| PL (1) | PL3030557T3 (enExample) |
| PT (1) | PT3030557T (enExample) |
| RS (1) | RS64477B1 (enExample) |
| RU (1) | RU2636585C2 (enExample) |
| SG (1) | SG11201600549TA (enExample) |
| SI (1) | SI3030557T1 (enExample) |
| SM (1) | SMT202300268T1 (enExample) |
| WO (1) | WO2015037939A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| CA3129516A1 (en) * | 2018-02-28 | 2019-09-06 | The Trustees Of The University Of Pennsylvania | Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents |
| KR102913343B1 (ko) * | 2020-04-21 | 2026-01-15 | 아이디언스 주식회사 | 프탈라지논 화합물의 결정형 |
| WO2021214502A1 (en) * | 2020-04-21 | 2021-10-28 | Idience Co., Ltd. | Process for preparing a phthalazinone derivative and intermediates thereof |
| US20230159469A1 (en) * | 2020-05-08 | 2023-05-25 | Txinno Bioscience Inc. | Novel phthalazine derivative having ectonucloeotide pyrophosphatase/phosphodieste rase inhibitory activity, and use thereof |
| US12059419B2 (en) * | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| US20230391752A1 (en) * | 2020-10-22 | 2023-12-07 | Chulalongkorn University | Pyrrolidine-3-carboxamide derivatives and related uses |
| KR102977180B1 (ko) * | 2021-03-04 | 2026-06-15 | 아이디언스 주식회사 | Parp 억제제에 내성을 가진 환자군의 암 치료제로서의 프탈라지논 유도체의 항암제 용도 |
| WO2022186649A1 (ko) * | 2021-03-04 | 2022-09-09 | 아이디언스 주식회사 | Parp 억제제에 내성을 가진 환자군의 암 치료제로서의 프탈라지논 유도체의 항암제 용도 |
| TW202313040A (zh) * | 2021-06-02 | 2023-04-01 | 南韓商愛迪恩斯股份有限公司 | 以酞嗪酮衍生物治療病症的方法 |
| EP4469051A4 (en) * | 2022-01-25 | 2025-12-17 | Idience Co Ltd | Pharmaceutical composition with phthalazine derivative for simultaneous administration with an anticancer agent |
| WO2024025389A1 (ko) * | 2022-07-29 | 2024-02-01 | 아이디언스 주식회사 | 프탈라지논 유도체의 중간체의 제조방법 |
| CN117229260B (zh) * | 2023-11-13 | 2024-02-27 | 中国药科大学 | DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| DE60335359D1 (de) | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
| PL1633724T3 (pl) * | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| JP5271897B2 (ja) | 2006-05-31 | 2013-08-21 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | ポリ（ＡＤＰ−リボース）ポリメラーゼ（ＰＡＲＰ）の阻害剤としての、ピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン及びピロロ［１，２−ｄ］［１，２，４］トリアジン−１（２Ｈ）−オン誘導体 |
| MX347085B (es) | 2006-12-28 | 2017-04-06 | Abbott Laboratories * | Inhibidores de la poli (adp-ribosa) polimerasa. |
| CN101030723A (zh) | 2007-04-04 | 2007-09-05 | 钟志华 | 电磁变相发动机 |
| JP5758630B2 (ja) | 2007-11-15 | 2015-08-05 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Ｐａｒｐ阻害剤としてのピリダジノン誘導体 |
| AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2012014221A1 (en) | 2010-07-27 | 2012-02-02 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors |
| CN102372706A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372698A (zh) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| EP2646428B1 (en) | 2010-12-02 | 2016-06-01 | Shanghai De Novo Pharmatech Co Ltd. | Heterocyclic derivatives, preparation processes and medical uses thereof |
| CN102485721B (zh) | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
| CN103130723B (zh) * | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
-
2014
- 2014-09-11 KR KR1020140120152A patent/KR101670126B1/ko active Active
- 2014-09-12 SI SI201432038T patent/SI3030557T1/sl unknown
- 2014-09-12 DK DK14843941.7T patent/DK3030557T3/da active
- 2014-09-12 US US16/447,174 patent/USRE49338E1/en active Active
- 2014-09-12 SG SG11201600549TA patent/SG11201600549TA/en unknown
- 2014-09-12 CN CN201480049174.5A patent/CN105793248B/zh active Active
- 2014-09-12 BR BR112016004979-9A patent/BR112016004979B1/pt active IP Right Grant
- 2014-09-12 MY MYPI2016700730A patent/MY195343A/en unknown
- 2014-09-12 AU AU2014319132A patent/AU2014319132C1/en active Active
- 2014-09-12 FI FIEP14843941.7T patent/FI3030557T3/fi active
- 2014-09-12 LT LTEPPCT/KR2014/008523T patent/LT3030557T/lt unknown
- 2014-09-12 HU HUE14843941A patent/HUE062770T2/hu unknown
- 2014-09-12 PL PL14843941.7T patent/PL3030557T3/pl unknown
- 2014-09-12 EP EP14843941.7A patent/EP3030557B1/en active Active
- 2014-09-12 WO PCT/KR2014/008523 patent/WO2015037939A1/en not_active Ceased
- 2014-09-12 US US15/021,336 patent/US9682973B2/en active Active
- 2014-09-12 PT PT148439417T patent/PT3030557T/pt unknown
- 2014-09-12 RS RS20230721A patent/RS64477B1/sr unknown
- 2014-09-12 HR HRP20230998TT patent/HRP20230998T1/hr unknown
- 2014-09-12 RU RU2016108038A patent/RU2636585C2/ru active
- 2014-09-12 CA CA2923614A patent/CA2923614C/en active Active
- 2014-09-12 JP JP2016542643A patent/JP6180643B2/ja active Active
- 2014-09-12 ES ES14843941T patent/ES2953834T3/es active Active
- 2014-09-12 SM SM20230268T patent/SMT202300268T1/it unknown
- 2014-09-12 MX MX2016002998A patent/MX379467B/es unknown
-
2016
- 2016-03-11 IL IL244548A patent/IL244548B/en active IP Right Grant
-
2017
- 2017-03-10 US US15/455,631 patent/US9844550B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014319132C1 (en) | A novel phtalazinone derivatives and manufacturing process thereof | |
| CN115515947B (zh) | Shp2抑制剂及其组合物和应用 | |
| JP7611278B2 (ja) | 金属酵素阻害剤化合物 | |
| JP6419990B2 (ja) | ブロモドメイン阻害剤としてのベンゾイミダゾール誘導体 | |
| KR102106765B1 (ko) | 폴리엔 마크로라이드 유도체 | |
| CN107567454B (zh) | 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物及其类似物 | |
| EP3660013A1 (en) | Sgc stimulators | |
| WO2021139595A1 (zh) | RORγt抑制剂及其制备方法和用途 | |
| CN112513020A (zh) | 用于治疗疾病的kdm1a抑制剂 | |
| CN112513021A (zh) | RORγ拮抗剂及其在药物中的应用 | |
| CN113072476B (zh) | RORγt抑制剂及其制备方法和用途 | |
| HK1224280B (en) | Phtalazinone derivatives and manufacturing process thereof | |
| TWI810547B (zh) | Pd-l1拮抗劑化合物 | |
| HK40097687B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| EA047452B1 (ru) | Биарильные производные в качестве ингибиторов белок-белкового взаимодействия yap/taz-tead |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160307 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240822 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241011 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250715 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250715 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260630 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260630 |